Arvinas to Participate in Upcoming Investor Conferences
Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two upcoming investor conferences. Management will engage in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Cantor Global Healthcare Conference on September 5.
Live audio webcasts of both presentations will be accessible through the company's website under the "Events and Presentations" section of the Investors and Media page.
Arvinas (NASDAQ:ARVN), una società biotech in fase clinica focalizzata sulla degradazione mirata delle proteine, ha annunciato la partecipazione a due prossimi convegni per investitori. Il management terrà dei fireside chat il 4 settembre al Wells Fargo Healthcare Conference e il 5 settembre al Cantor Global Healthcare Conference.
I webcast audio in diretta di entrambe le presentazioni saranno disponibili sul sito web della società nella sezione "Eventi e Presentazioni" della pagina Investitori e Media.
Arvinas (NASDAQ:ARVN), una biotecnológica en fase clínica centrada en la degradación dirigida de proteínas, ha anunciado su participación en dos próximas conferencias para inversores. La dirección participará en charlas informales (fireside chats) el 4 de septiembre en la Wells Fargo Healthcare Conference y el 5 de septiembre en la Cantor Global Healthcare Conference.
Las retransmisiones de audio en directo de ambas presentaciones estarán accesibles a través del sitio web de la compañía en la sección "Eventos y Presentaciones" de la página de Inversores y Medios.
Arvinas (NASDAQ:ARVN)는 표적 단백질 분해를 연구하는 임상 단계 바이오테크 기업으로, 다가오는 두 건의 투자자 컨퍼런스에 참가한다고 발표했습니다. 경영진은 9월 4일 Wells Fargo Healthcare Conference와 9월 5일 Cantor Global Healthcare Conference에서 파이어사이드 챗(fireside chats)에 참여할 예정입니다.
두 발표의 라이브 오디오 웹캐스트는 회사 웹사이트의 "Events and Presentations" 섹션, 투자자 및 미디어 페이지를 통해 들을 수 있습니다.
Arvinas (NASDAQ:ARVN), une société biotechnologique en phase clinique spécialisée dans la dégradation ciblée des protéines, a annoncé sa participation à deux prochaines conférences pour investisseurs. La direction prendra part à des fireside chats le 4 septembre lors du Wells Fargo Healthcare Conference et le 5 septembre lors du Cantor Global Healthcare Conference.
Les webcasts audio en direct des deux présentations seront accessibles via le site Web de la société dans la section "Événements et Présentations" de la page Investisseurs et Médias.
Arvinas (NASDAQ:ARVN), ein Biotech-Unternehmen in klinischer Phase mit Schwerpunkt auf gezieltem Proteinabbau, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Management wird an Fireside-Chats am 4. September beim Wells Fargo Healthcare Conference und am 5. September beim Cantor Global Healthcare Conference teilnehmen.
Live-Audio-Webcasts beider Präsentationen sind über die Website des Unternehmens unter dem Bereich "Events and Presentations" auf der Seite für Investoren und Medien zugänglich.
- None.
- None.
NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats at two upcoming investor conferences:
- Wells Fargo Healthcare Conference on Thursday, September 4. A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.
- Cantor Global Healthcare Conference on Friday, September 5. A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When is Arvinas (ARVN) presenting at the Wells Fargo Healthcare Conference 2025?
When is Arvinas (ARVN) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Arvinas (ARVN) conference presentations in September 2025?
What type of company is Arvinas (ARVN)?
